Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients

Surgery Today

Volumn 41, Issue 4, 2011, Pages 471-476

  Mishra, Anjali ^a   Chandra, Richa ^b   Mehrotra, Prateek Kumar ^a   Bajpai, Prachi ^b   Agrawal, Deepa ^b  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Neoadjuvant chemotherapy; Predicted response to chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PROTEIN FUNCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POLYMORPHISM, GENETIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79956205042     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-009-4310-4     Document Type: Article

References (29)

1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005;6:391-401. (Pubitemid 43078894)
2. Bafaloukos D. Neo-adjuvant therapy in breast cancer. Ann Oncol 2005;16(s-2):174-81.
3. Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 2005;12:73-85.
4. Vyzula R, Dusek L, Zaloudík J, Demlová R, Klimes D, Selvekerová S. Breast cancer and neoadjuvant therapy: any predictive marker? Neoplasma 2004;51:471-80.
5. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003;88:406-12. (Pubitemid 36308152)
6. Bosh TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45:253-85. (Pubitemid 43327492)
7. Stearns V, Davisson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenenomics J 2004;4:143-53. (Pubitemid 38786552)
8. Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, et al. Association between drug metabolism genotype, chemotherapy pharmacokinetics and overall survival in patient with breast cancer. J Clin Oncol 2005;23:6117-25.
9. Yang G, Shu X-O, Ruan Z-X, Cai QY, Jin F, Gao Y-T, et al. Genetic polymorphism in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinomas. Cancer 2005;103:52-8. (Pubitemid 39665456)
10. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 1998;16:2672-85.
11. Pierga JY, Mouret E, Laurence V, Diéras V, Savigioni A, Beuzeboc P, et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response Eur J Cancer 2003;39:1089-96.
12. Lizard-Nacol S, Coudert B, Colosetti P, Riedinger J-M, Fargeot P, Brunet-Lecome P. Glutathione S transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res 1999;1:81-7. (Pubitemid 32223550)
13. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422-31. (Pubitemid 46224217)
14. Therasse P, ArbucSG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
15. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolic gene glutathione-S-transferase M1 (GSTM1) that increases the susceptibility to bladder cancer. J Natl Cancer Inst 1993;85:1159-64. (Pubitemid 23212283)
16. Pemble TR. Molecular epidemiology of the human glutathione-S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-43.
17. Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Hoffman S, Alberg AJ, et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 1998;90:512-8. (Pubitemid 28182544)
18. Board PG. Gene deletion and partial deficiency of the glutathione S-transferase (ligandin) system in man. FEBS Lett 1981;135:2-4.
19. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione-S-transferase (GSTT1) cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-6. (Pubitemid 24151046)
20. Hayes JD, Pulford DJ. The glutathione-S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
21. Mishra DK, Kumar A, Srivastava DS, Mittal RD. Allelic variation of GSTT1, GSTM1 and GSTP1 genes in North Indian population. Asian Pac J Cancer Prev 2004;5:362-5.
22. Vettriselvi V, Vijayalakshmi K, Paul SF, Venkatachalam P. Genetic variation of GSTT1, GSTM1 and GSTP1 genes in a South Indian population Asian Pac J Cancer Prev2006;7:325-8.
23. Syamala VS, Sreeja L, Syamala V, Raveendran PB, Balakrishnan R, Kuttan R, et al. Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival. Fam Cancer 2008;7:213-20.
24. Bai F, Nakanishi Y, Kawasaki M, Takayama K, Yatsunami J, Pei XH, et al. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer 1996 1;78:416-21. (Pubitemid 26250525)
25. Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999;5:4097-104. (Pubitemid 30013791)
26. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006;368:93-8. (Pubitemid 43776023)
27. Mossallam GI, Abdel Hamid TM, Samra MA. Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. J Egypt Natl Cancer Inst 2006;18:264-73.
28. Barahmani N, Carpentieri S, Li XN, Wang T, Cao Y, Howe L, et al. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. NeuroOncology 2009;11:292-300.
29. Oldenburg J, Kraggerud SM, Brydøy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007;5:70.